The pharmaceutical industry says a popular class of targeted cancer therapies could one day replace chemotherapy and its potential for harsh side effects. There is still more work to be done to refine ...

Today from the team at Cesanta Software — the people who gave us the open-source Mongoose Web Server Library and Mongoose OS — we have an article covering how to build an STM32 web dashboard. The ...

Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to deliver ...

Robbie has been an avid gamer for well over 20 years. During that time, he's watched countless franchises rise and fall. He's a big RPG fan but dabbles in a little bit of everything. Writing about ...

ADC Therapeutics has stopped development of lead solid tumor candidate ADCT-601. The biotech axed the AXL-directed antibody-drug conjugate (ADC) after failing to show a favorable benefit-risk profile ...

Callum is a seasoned gaming managing editor for a number of publications and a gamer who will always try to shine a spotlight on indie games before giving AAA titles the time of day. He loves nothing ...

AI tools are the latest craze to impact the tech industry — and by extension, the rest of the world. For years now, bosses everywhere are trying to boost profits by replacing workers with AI, and ...

Despite some positive trials with new drugs (including immunotherapy) for recurrent cervical cancer, the prognosis for this disease remains poor and additional treatment options are needed. Tisotumab ...

In the second setback for the HER3 field in days, the FDA has rejected Daiichi Sankyo’s Merck & Co.-partnered antibody-drug conjugate (ADC) patritumab deruxtecan. The drug, also known as HER3-DXd, was ...

Coverage of a session on antibody drug conjugates from the 2024 American Society of Clinical Oncology Annual Meeting. Updates about antibody-drug conjugates (ADCs) were coming so fast at the 2024 ...

An open-label, multicenter, phase I study of ATG-022 in patients with advanced/metastatic solid tumors (CLINCH). The design, preclinical study and phase I dose escalation plan of a HER2 targeted ...

What comes to mind when you think of a slime tutorial? Hundreds of videos of children using glue and borax to make some horrifying concoction, perhaps? For the theater community, the phrase’s meaning ...